BioCentury
ARTICLE | Finance

Banker tracks

Biotech investor, banker and analyst personnel changes

April 1, 2013 7:00 AM UTC

Jeffrey Goater departed Evercore Partners as a managing director. He joined rare disease company Synageva BioPharma Corp. (NASDAQ:GEVA) as VP of business development. In February, Synageva started a Phase III trial of its sebelipase alfa to treat late onset lysosomal acid lipase (LAL) deficiency.

David Donabedian joined AbbVie Biotech Ventures as a managing director. He was an SVP at Locust Walk Partners...